https://orcid.org/0000-0002-5387-0013
References
- Pines JM, Poarch K, Hughes S. Recognition and differential diagnosis of hereditary angioedema in the emergency department. J Emerg Med. 2021;60(1):35–43.
- Bernstein JA, Cremonesi P, Hoffmann TK, et al. Angioedema in the emergency department: a practical guide to differential diagnosis and management. Int J Emerg Med. 2017;10(1):15.
- Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema- The 2017 revision and update. Allergy. 2018;73(8):1575–1596.
- Bork K, Hardt J, Schicketanz KH, et al. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med. 2003;163(10):1229–1235.
- Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012;130(3):692–697.
- Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75(4):349–354.
- Harnett KP, Kite-Powell A, DeVies J, et al. Impact of the COVID-19 pandemic on emergency department visits — United States, January 1, 2019–May 30, 2020. MMWR. 2020;69( 23):699–704.
- Bernstein JA, Moellman J. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med. 2012;5(1):39.
- Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med (Lond). 2019;80(7):391–398.
- Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol. 2015;136(2):245–251.
- Wöhrl S. NSAID hypersensitivity – recommendations for diagnostic work up and patient management. Allergo J Int. 2018;27(4):114–121.
- Bork K. Angioedema. Immunol Allergy Clin North Am. 2014;34(1):23–31.
- Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69(5):602–616.
- Grumach AS, Goudouris E, Dortas Junior S, et al. COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2021;9(1):508–510.
- Castelli R, Zanichelli A, Cicardi M, et al. Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationship. Crit Rev Oncol Hematol. 2013;87(3):323–332.
- Cicardi M, Suffritti C, Perego F, et al. Novelties in the diagnosis and treatment of angioedema. J Investig Allergol Clin Immunol. 2016;26(4):212–221.
- Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132–150.
- Saff RR, Banerji A. Management of patients with nonaspirin-exacerbated respiratory disease aspirin hypersensitivity reactions. Allergy Asthma Proc. 2015;36(1):34–39.
- Belbézier A, Arnaud M, Boccon-Gibod I, et al. COVID-19 as a trigger of acute attacks in people with hereditary angioedema. Clin Exp Allergy. 2021;51(7):947–950.
- KALBITOR®. Package insert. Dyax Corp; 2009.